Company Filing History:
Years Active: 2019-2024
Title: The Innovative Contributions of Carmine Carpenito
Introduction
Carmine Carpenito is a notable inventor based in Hartsdale, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 2 patents to his name, Carpenito's work focuses on advancing cancer treatment options.
Latest Patents
Carpenito's latest patents include groundbreaking inventions that target specific proteins involved in tumor growth. The first patent, titled "Anti-CD137 antibodies for combination with anti-PD-L1 antibodies," relates to antibodies that bind to human CD137 and exhibit agonist activity. This invention may be useful for treating both solid and hematological tumors, either alone or in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation. The second patent, "Anti-Tim-3 antibodies," involves antibodies that bind to human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3). This invention also holds promise for treating solid and hematological tumors in conjunction with chemotherapy and ionizing radiation.
Career Highlights
Carmine Carpenito is currently employed at Eli Lilly and Company, where he continues to innovate in the field of cancer therapeutics. His work has the potential to significantly impact treatment protocols and improve patient outcomes.
Collaborations
Throughout his career, Carpenito has collaborated with talented individuals such as Yiwen Li and Yi Zhang. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in biotechnology.
Conclusion
Carmine Carpenito's contributions to the field of biotechnology through his patents and collaborations highlight his commitment to advancing cancer treatment. His work exemplifies the importance of innovation in improving healthcare outcomes.